Save the Date: March 14 - 15 2022.

We are delighted to announce that the WIN 2022 symposium will take place in person on March 14-15 2022 in Barcelona, Spain.

The 2-day symposium will develop the theme INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY: A WINNING STRATEGY in live plenary sessions followed by discussion panels and Q&A.

The symposium committee is delighted to share with you the scientific program with worldwide experts. 

grwrgergergr

Symposium Committee Chairs

Image Description
Richard L. Schilsky
MD, FACP, FSCT, FASCO

Chairman, WIN Consortium, Professor Emeritus, University of Chicago
Past President and Former Executive Vice President and Chief Medical Officer (ASCO), USA

Image Description
Josep Tabernero
MD, PhD

Vice Chairman, WIN Consortium, Head, Medical Oncology Department,
Vall d’Hebron Institute of Oncology, President 2018 - 2019, European Society for Medical Oncology (ESMO)

Symposium Committee Members

Image Description
Gerald Batist
MD, CM, CQ, FRCP(C), FACP, FCAHS

Professor of Medicine and Oncology at McGill University, Director of the Segal Cancer Centre, Canada

Image Description
Vladimir Lazar
PhD

Chief Scientific and Operating Officer, WIN Consortium, France

Image Description
Amir Onn
PhD

Head of Standard Operating Procedures and Repository Committee, WIN Consortium Chair, Institute of Pulmonology Oncology, Sheba Medical Center, Israel

Image Description
Razelle Kurzrock
MD

Chief Medical Officer, WIN Consortium

Program Activities

March 14, 2021

08:30  Welcome and Opening Remarks - What The Future Holds in Precision Oncology
09:20 Session 1 - Beyond DNA Testing: The Place of Transcriptomics in Precision Oncology
14:30 Session 2 -Innovation in Clinical Trials to Enable Future Efficient Treatments
16:45 Poster viewing, networking
18:00 Satellite symposium (to be confirmed)
19:00 Poster viewing, welcome reception 
20:00 Symposium dinner

March 15, 2021

08:30 Session 3 - Disruptive Concepts and Methodological Innovations in NSCLC: Meet the Experts
11:30 Session 4 - WIN First International Molecular Tumor Board: A Strategic Place in Advancing Precision Oncology
14:00 Session 5 - What is New in Breast, CRC, Ovary, Head & Neck, Prostate, Kidney, Pediatric Cancers?
16:55 Best Two Posters Presentations and Awards
17:20 Conclusions

Audience

The audience of the Symposium spans a wide range of high-profile stakeholders in clinical and non-clinical cancer research, technology development and patient management.  WIN Symposia attracts an international audience with 50% coming from Europe, 25% from Americas, 15% Middle East & Africa and 10% Asia & Oceania. 

Attendees who are for the vast majority (80%) physicians (or physicians in training), need to understand the role of the current biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.

Expected Outcomes Impact

Treating patients without understanding the established and emerging molecular markers for cancer can affect virtually every patient with cancer and every aspect of cancer care, since there are multiple FDA and EMA approved omic biomarkers to refine prognosis, select therapy and/or clinical trials and monitor for cancer recurrence.

There are now biomarkers for selection of hormonal therapies, targeted therapies and immunotherapy. We would like attendees to understand the role of these biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.

We will discuss in particular the inclusion of transcriptomics in the biomarker armamentarium, that will require novel algorithms and improved quality of biopsies.

The symposium will also present its first international Molecular Tumor Board to exemplify with patients' concrete cases, submitted by meeting attendees, how to use biomarkers to inform therapeutic choice.

Learning Objectives

The overall learning objectives are: 

  1. List available biomarkers for choosing cancer therapy
  2. Understand the limitations of current genomic-based biomarkers
  3. Understand the objectives and design of research studies and clinical trials assessing new biomarkers for immunotherapy and targeted therapy
  4. Understanding differences between prognostic and predictive biomarkers.

CME

The CME request for the WIN 2022 Symposium is pending, for 13 hours of European external CME credits by the European Accreditation Council for Continuing Medical Education (EACCME®).

EACCME Credits 

The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu 

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/cme/claim-cme-credit-ama

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. 

Accreditations - Past Endorsing Organizations

  • American Society of Clinical Oncology (ASCO®). The WIN symposia have been endorsed by ASCO for the past 11 consecutive years.
  • European School of Oncology (ESO) 

Endorsement applications are currently under preparation. 

Information on registration and abstract submission will be released on this website, make sure you have registered your interest to receive updates 

WIN Symposium series endorsed by:

ASCO® is a registered trademark of the American Society of Clinical Oncology®.
Used with permission. This is not an ASCO sponsored event.

WIN series recommended by:

Join Us at Our Annual Symposium: 

Listen to 30 Precision Oncology leaders from academia, industry and research organizations.


View over 70 thought provoking abstracts from like-minded professionals.


Showcase your work.


Engage in the open discussions and network with other professionals in oncology.

Interested in Learning More?

See the WIN 2019 Presentations

WIN 2022 Symposium
c/o MCI UK Ltd
Durford Mill
Petersfield
GU31 5AZ

Tel: +44 (0) 1730 715223
General enquiries: winsymposium@mci-group.com
Sponsorship enquiries: winsymposium@mci-group.com
Abstract enquiries: winsympabstracts@mci-group.com
Registration enquiries: winsympreghot@mci-group.com

View Our Privacy Policy Here